Company intelligence / Profile preview

Sarah Cannon Research Institute

Nashville, Tennessee, United Statesscri.com ↗

Ownership: Private
Employees: ~350
Development stage: Commercial

Overview

Sarah Cannon Research Institute has conducted more than 850 first-in-human clinical trials since inception in 1993. It has contributed to pivotal research leading to the majority of new cancer therapies approved by the FDA over the past decade. The organization manages hundreds of active oncology studies annually at nearly 250 locations across more than 20 states in the U.S., with significant impact on early-phase drug development.

Therapeutic areas: OncologyCardiovascularGastroenterology
Modalities: Small moleculeMonoclonal antibodyCell therapy (including CAR-T cell therapy)
Industry: Contract Research Organization

Partnerships

AbbVieBostonGene

Beyond the preview

Go deeper on Sarah Cannon Research Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sarah Cannon Research Institute.

Explore the full profile